118th Congress Health
S. 775: Increasing Transparency in Generic Drug Applications Act
Introduced
- Introduced (completed)
- Passed Senate (not reached)
- Passed House (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Cosponsors
- Rand Paul R-KYOriginal
- Mike Braun R-IN
- John Hickenlooper D-CO
Who scored on this bill
- 1Margaret Hassan SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
Other bills by Margaret Hassan
- S. 2801: Canterbury Shaker Village National Heritage Area Study Authorization Act
- S. 3211: Recognizing the Role of Direct Support Professionals Act
- S. 850: Northern Border Security Enhancement and Review Act
- S. 2658: Medication Affordability and Patent Integrity Act
- S. 380: Rural Obstetrics Readiness Act
- S. 1602: Mathematical and Statistical Modeling Education Act
History
- Introduced in the Senate by Margaret Hassan.
Show the full action history (2 actions)
- Introduced in Senate
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.